Treatment C for Healthy Subjects (HS)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Research Site, Brooklyn, MD
Healthy Subjects (HS)
AZD5462 - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study will assess the pharmacokinetics of AZD5462 film-coated tablet formulation in healthy participants.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Healthy Subjects (HS)

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: Day 1 to Day 17

Day 17
Area under plasma concentration time curve from zero to infinity (AUCinf)
Area under the plasma concentration-curve from time zero to last quantifiable concentration (AUClast)
Maximum observed plasma (peak) drug concentration [Cmax]
Until follow-up (Day 21)
Number of participants with Adverse Events (AEs), and Serious Adverse Events (SAEs)

Trial Safety

Safety Progress

1 of 3

Other trials for Healthy Subjects (HS)

Trial Design

6 Treatment Groups

Treatment C
1 of 6
Treatment F
1 of 6
Treatment D
1 of 6
Treatment A
1 of 6
Treatment E
1 of 6
Treatment B
1 of 6
Experimental Treatment

16 Total Participants · 6 Treatment Groups

Primary Treatment: Treatment C · No Placebo Group · Phase 1

Treatment C
Drug
Experimental Group · 1 Intervention: AZD5462 · Intervention Types: Drug
Treatment F
Drug
Experimental Group · 1 Intervention: AZD5462 · Intervention Types: Drug
Treatment D
Drug
Experimental Group · 1 Intervention: AZD5462 · Intervention Types: Drug
Treatment A
Drug
Experimental Group · 1 Intervention: AZD5462 · Intervention Types: Drug
Treatment E
Drug
Experimental Group · 1 Intervention: AZD5462 · Intervention Types: Drug
Treatment B
Drug
Experimental Group · 1 Intervention: AZD5462 · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 to day 17
Closest Location: Research Site · Brooklyn, MD
1900First Recorded Clinical Trial
311 TrialsResearching Healthy Subjects (HS)
2948 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have provided written informed consent prior to any study specific procedures.
You are a healthy male or female aged 18 to 55 years.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.